**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

ACTAVIS, INC., ACTAVIS LABORATORIES FL, INC., ACTAVIS PHARMA, INC., AMNEAL PHARMACEUTICALS, LLC, AMNEAL PHARMACEUTICALS OF NEW YORK, LLC, AUROBINDO PHARMA LTD., AUROBINDO PHARMA USA, INC., BRECKENRIDGE PHARMACEUTICAL, INC., VENNOOT PHARMACEUTICALS, LLC, SANDOZ INC., SUN PHARMA GLOBAL FZE, and SUN PHARMACEUTICAL INDUSTRIES, LTD.,
Petitioners

v.

RESEARCH CORPORATION TECHNOLOGIES, INC.,
Patent Owner

---

Case: IPR2014-01126

---

**DECLARATION OF CLAYTON H. HEATHCOCK, PH.D. IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. RE 38,551**

Mail Stop PATENT BOARD
Patent Trial and Appeal Board
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313–1450
*Submitted Electronically via the Patent Review Processing System*

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

## TABLE OF CONTENTS


Exhibits Referenced In This Declaration ..... iv

I. INTRODUCTION AND QUALIFICATIONS ..... 1

A. Educational Background ..... 1

B. Career History and Relevant Industry Participation ..... 2

II. SCOPE OF ASSIGNMENT AND COMPENSATION ..... 5

III. LEGAL PRINCIPLES USED IN MY ANALYSIS ..... 6

A. Person of Ordinary Skill in the Art ..... 6

B. Prior Art ..... 7

C. Anticipation ..... 8

D. Obviousness ..... 9

IV. SUMMARY OF MY OPINIONS ..... 10

V. THE '551 PATENT ..... 11

A. Overview of the '551 Patent – The Alleged Invention ..... 11

B. Overview of Claims 1-13 of the '551 Patent ..... 11

C. Claim Construction of the '551 Patent ..... 14

VI. TECHNICAL BACKGROUND ..... 15

A. Representation of Chemical Structures ..... 15

B. Amino Acids ..... 19

C. Stereochemistry ..... 21

D. Background on Drug Development ..... 27

VII. CLAIMS 1-13 OF THE '551 PATENT ARE ANTICIPATED BY THE '301 PATENT ..... 28



DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

A. The '301 Patent Discloses Lacosamide....29

B. The Preferences Disclosed by the '301 Patent Lead Directly to One Compound—Lacosamide—in Claim 44....32

C. Claims 1-9 of the '551 Patent are Anticipated by the '301 Patent....34

D. Claim 10 of the '551 Patent is Anticipated by the '301 Patent....36

E. Claims 11-13 of the '551 Patent are Anticipated by the '301 Patent....37

VIII. CLAIMS 1-13 OF THE '551 PATENT ARE ANTICIPATED BY THE LEGALL THESIS....38

A. The LeGall Thesis Discloses Racemic Lacosamide as an Anticonvulsant Compound....39

B. A POSA was Enabled by the LeGall Thesis and the Prior Art to Isolate the R Enantiomer, Lacosamide, in Pure Form....42

C. Claims 1-9 of the '551 Patent are Anticipated by the LeGall Thesis....46

D. Claim 10 of the '551 Patent is Anticipated by the LeGall Thesis....47

E. Claims 11-13 of the '551 Patent are Anticipated by the LeGall Thesis....48

IX. CLAIMS 1-13 OF THE '551 PATENT ARE OBVIOUS....49

A. The Scope and Content of the Prior Art....50

1. Structure-Activity Relationships Were Well-Known For The Class Of Compounds Covered By The '551 Patent....50

2. The Substitution of Methyl for Amino Groups was Commonly Performed in the Prior Art....78

3. The Prior Art Taught The Preparation Of Enantiomerically Pure D-Serine And Its Derivatives....80

B. The Differences Between the Prior Art and Claims....83

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

1. Claims 1 and 3-8 of the '551 Patent Would Have Been Obvious in View of the LeGall Thesis and Other Prior Art.....83

2. Claims 2 and 9 of the '551 Patent Would Have Been Obvious in View of the LeGall Thesis and Other Prior Art.....96

3. Claim 10 of the '551 Patent Would Have Been Obvious in View of the LeGall Thesis and Other Prior Art.....99

4. Claims 11-13 of the '551 Patent Would Have Been Obvious in View of the LeGall Thesis and Other Prior Art...102

C. The Level of Ordinary Skill in the Art.....109

D. Secondary Considerations or Objective Indicia of Nonobviousness.....109

X. CONCLUSION.....109

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

## EXHIBITS REFERENCED IN THIS DECLARATION

| Exhibit | Description |
|---|---|
| 1001 | U.S. Patent No. RE 38,551 to Kohn ("'551 patent") (reissue of U.S. Patent No. 5,773,475 ("'475 patent")) |
| 1003 | U.S. Patent No. 5,654,301 to Kohn and Watson (the "'301 patent") |
| 1004 | Jan. 28, 1998 Notice of Allowability (excerpt from prosecution history of '475 patent) |
| 1005 | Philippe LeGall, *2-Substituted-2-acetamido-N-benzylacetamides. Synthesis, Spectroscopic and Anticonvulsant Properties* (Dec. 1987) ("LeGall thesis") |
| 1006 | Apr. 10, 1998 Amendment Under 37 C.F.R. § 1.312 (excerpt from prosecution history of '475 patent) |
| 1008 | U.S. Patent No. 5,378,729 to Kohn and Watson ("'729 patent") |
| 1009 | Sergio Cortes et al., *Effect of Structural Modification of the Hydantoin Ring on Anticonvulsant Activity*, 28 J. Med. Chem. 601 (1985) ("Cortes") |
| 1010 | Harold Kohn et al., *Preparation and Anticonvulsant Activity of a Series of Functionalized α-Heteroatom-Substituted Amino Acids*, 34 J. Med. Chem. 2444 (1991) ("Kohn 1991") |
| 1012 | U.S. Provisional Patent Application No. 60/013,522 ("'522 prov. app.") |
| 1014 | Phillipe LeGall et al., *Synthesis of Functionalized Non-Natural Amino Acid Derivatives via Amidoalkylation Transformations*, 32 Int'l J. Peptide Protein Res. 279 (1988) ("LeGall 1988") |
| 1015 | R. L. M. Synge, *CCXXXIX. Experiments On Amino Acids. IV. The Methyl Ethers Of Some N-Acetyl-Hydroxyamino-* |

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

DOCKET ALARM

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

**LAW FIRMS**
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

**FINANCIAL INSTITUTIONS**
Litigation and bankruptcy checks for companies and debtors.

**E-DISCOVERY AND LEGAL VENDORS**
Sync your system to PACER to automate legal marketing.